Drug Profile
Research programme: controlled-release stem cell therapeutics - Cell Care Therapeutics
Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Cell Care Therapeutics
- Class Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Parenteral)
- 23 Oct 2018 Preclinical trials in Diabetic retinopathy and Wet age-related macular degeneration in USA (Parenteral)